1. Home
  2. JAGX vs CDT Comparison

JAGX vs CDT Comparison

Compare JAGX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • CDT
  • Stock Information
  • Founded
  • JAGX 2013
  • CDT 2019
  • Country
  • JAGX United States
  • CDT United States
  • Employees
  • JAGX N/A
  • CDT N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • JAGX Health Care
  • CDT Health Care
  • Exchange
  • JAGX Nasdaq
  • CDT Nasdaq
  • Market Cap
  • JAGX 3.9M
  • CDT 4.6M
  • IPO Year
  • JAGX N/A
  • CDT N/A
  • Fundamental
  • Price
  • JAGX $1.97
  • CDT $0.67
  • Analyst Decision
  • JAGX Strong Buy
  • CDT
  • Analyst Count
  • JAGX 1
  • CDT 0
  • Target Price
  • JAGX $60.00
  • CDT N/A
  • AVG Volume (30 Days)
  • JAGX 140.0K
  • CDT 2.3M
  • Earning Date
  • JAGX 11-12-2025
  • CDT 11-13-2025
  • Dividend Yield
  • JAGX N/A
  • CDT N/A
  • EPS Growth
  • JAGX N/A
  • CDT N/A
  • EPS
  • JAGX N/A
  • CDT N/A
  • Revenue
  • JAGX $11,810,000.00
  • CDT N/A
  • Revenue This Year
  • JAGX $22.41
  • CDT N/A
  • Revenue Next Year
  • JAGX $30.00
  • CDT N/A
  • P/E Ratio
  • JAGX N/A
  • CDT N/A
  • Revenue Growth
  • JAGX 15.96
  • CDT N/A
  • 52 Week Low
  • JAGX $1.57
  • CDT $0.57
  • 52 Week High
  • JAGX $35.25
  • CDT $274.80
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 49.42
  • CDT 20.06
  • Support Level
  • JAGX $1.88
  • CDT $0.57
  • Resistance Level
  • JAGX $2.16
  • CDT $1.36
  • Average True Range (ATR)
  • JAGX 0.12
  • CDT 0.09
  • MACD
  • JAGX 0.06
  • CDT -0.05
  • Stochastic Oscillator
  • JAGX 67.80
  • CDT 9.84

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: